Assessments of Multiple Breast Cancer Biomarkers with Dendritic MRI Probes

使用树突状 MRI 探针评估多种乳腺癌生物标志物

• 批准号: 7786531
• 负责人: Meser M. Ali
• 金额: $ 12.62万
• 依托单位: HENRY FORD HEALTH SYSTEM
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7786531
• 关键词: Accounting; Address; Animal Model; Bicarbonates; Binding; Biological Markers; Biomedical Engineering; Blood Vessels; Breast; Breast Cancer Cell; Breast Cancer Treatment; Cancer Biology; Cancer Patient; Cancer cell line; Cancerous; Cells; Characteristics; Chemicals; Chemistry; Cilengitide; Clinic; Contrast Media; Dendrimers; Detection; Development; Development Plans; Diagnosis; Diagnostic; Disease; Doxorubicin; Early Diagnosis; Environment; Evaluation; Goals; Growth; Hand; Image; Integrin Binding; Integrins; Lead; Lesion; Longitudinal Studies; MCF7 cell; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Mammary Neoplasms; Measurement; Measures; Mentors; Metastatic to; Methods; Molecular; Monitor; Neoplasm Metastasis; Pathology; Patients; Permeability; Phenotype; Process; Radiology Specialty; Relaxation; Research; Research Personnel; Specificity; Structure; Technology; Testing; Therapeutic; Therapeutic Effect; Tissues; Training; Translating; Treatment Efficacy; Tumor Angiogenesis; Tumor Tissue; Vascular Endothelial Growth Factors; Vascular Permeabilities; angiogenesis; anticancer research; base; bioimaging; cancer therapy; career development; chemotherapy; cyclo(S,S)KYGCRGDWPC; extracellular; imaging modality; imaging probe; improved; in vivo; malignant breast neoplasm; molecular imaging; mouse model; nanoparticle; nanoscale; nanosized; neovasculature; new technology; outcome forecast; programs; public health relevance; receptor; response; skills; tumor

DESCRIPTION (provided by applicant): A research and career development plan is proposed to transition from a background in chemistry to an independent research program in biomedical imaging and cancer biology. A two-tiered research plan will first focus on developing new MRI contrast agents, and then focus on applying these MRI contrast agents to mouse models of breast cancer. This research plan is founded on the development and application of new types of MRI contrast agents that can monitor multiple cancer biomarkers during a single MRI scan session. Our objectives of the proposed research are A) to develop a new T1 relaxation agent that can accurately measure the acidic extracellular pH of metastatic breast tumor tissues, while also accounting for the concentration of the agent by including a PARACEST MRI contrast agent; B) to develop a new PARACEST agent that targets v3 cell integrin; C) to combine these agents with a new PARACEST agent that can measure vascular permeabilities in order to assess tumor angiogenesis and D) to assess therapeutic responses in breast cancer mouse models by measuring extracellular pH, detecting v3 expression and evaluating vascular permeability during a single MRI scan session. Our deliverable consists of nano-sized dendrimers that can carry the MRI contrast agents for improved detection sensitivity, and for improved specificity for tumor tissues through the Enhanced Permeability and Retention effect. Successful completion of these specific aims will lead to evaluations of therapeutic efficacies that change tumor pH or v3 expression levels using our new MRI methods. This unique combination of nanoparticles and molecular imaging constitutes a platform technology for many other biomedical applications. A two-tiered career development plan will also be established. Training in biomedical imaging will be achieved through guidance by experts in biomedical engineering and radiology. A mentor committee will also provide guidance while navigating the activities required to establish a new research program. During the second year, senior mentors in cancer biology will provide guidance in cancer research applications and professional development activities. A progressive plan is also proposed to develop skills as a mentor, leader, networker, presenter, writer, collaborator, and entrepreneur throughout this process, in order to develop an independent, staffed and fully resourced research program in biomedical imaging and cancer research. PUBLIC HEALTH RELEVANCE: The results of this project will provide a direct method to measure in vivo pH non-invasively. Thus, the extracellular pH (pHe) within tumor tissues will be used as a diagnostic biomarker to determine the prognosis of pathology, to evaluate the efficacy of pHe-altering therapies and to predict the efficacy of pHe-dependent chemotherapies. Besides, multifunctional nano-sized MRI probes will be used to assess multiple, tumor specific biomarkers in a single MRI scan session and this novel technology will significantly enhance in the early diagnosis and treatment of breast cancer. In addition, a structured career development plan will make project PI as an independent investigator.

描述（由申请人提供）：提出了一项研究和职业发展计划，以从化学背景过渡到生物医学成像和癌症生物学领域的独立研究计划。两层研究计划将首先关注开发新的MRI对比剂，然后专注于将这些MRI对比剂应用于乳腺癌小鼠模型。该研究计划建立在新型的MRI对比剂的开发和应用上，这些MRI对比剂可以在一次MRI扫描过程中监测多个癌症生物标志物。我们提出的研究的目标是a）开发一种新的T1松弛剂，该剂可以准确地测量转移性乳腺肿瘤组织的酸性细胞外pH，同时还可以通过包括最有偏见的MRI对比剂来解决该药物的浓度； b）开发一种针对V3细胞整联蛋白的新的极偏剂； c）将这些药物与新的有偏剂剂相结合，该药物可以测量血管渗透性，以评估肿瘤血管生成和d）通过测量细胞外pH，检测V3表达并评估单个MRI SCAN疗程中的血管渗透性，以评估乳腺癌小鼠模型中的治疗反应。我们的可交付方式由纳米尺寸的树枝状聚合物组成，可以携带MRI对比剂以提高检测灵敏度，并通过增强的渗透性和保留效应来提高肿瘤组织的特异性。这些特定目标的成功完成将导致评估治疗功效，该治疗效率通过我们的新MRI方法改变肿瘤pH或V3表达水平。纳米颗粒和分子成像的独特组合构成了许多其他生物医学应用的平台技术。 还将制定一项两层职业发展计划。生物医学工程和放射学专家的指导将实现生物医学成像的培训。导师委员会还将在浏览建立新研究计划所需的活动时提供指导。在第二年，癌症生物学的高级导师将为癌症研究应用和专业发展活动提供指导。还提出了一项进步计划，以在整个过程中发展作为导师，领导者，网络，演示者，作家，合作者和企业家的技能，以制定一项独立，人员配备和全面资源的研究计划。 公共卫生相关性：该项目的结果将提供一种直接的方法来无创地测量体内pH。因此，肿瘤组织中的细胞外pH（PHE）将用作诊断生物标志物来确定病理的预后，评估改变PHE的疗法的疗效并预测pHE依赖性化学疗法的疗效。此外，多功能纳米尺寸的MRI探针将用于评估单个MRI扫描课程中的多种肿瘤特异性生物标志物，在早期诊断和治疗乳腺癌时，这种新型技术将显着增强。此外，结构化的职业发展计划将使PI项目成为独立研究者。